Hospital

Study results show that intravenous immunoglobulin therapy can help combat this type of PRCA in individuals with anemia.

As individuals in a society, all people have implicit, or unconscious, beliefs that they have been socialized to hold; however, health care professionals’ implicit biases can impact patients’ lives.

Pharmacy Times will be spotlighting pharmacists throughout the month of October to recognize their contributions to the health care field.

Phoenix-area Walgreens pharmacist Matthew Pruitt earns top honor as 2022 Pharmacist of the Year.

Biology and disease type may help determine which therapeutic options could work best for patients with Waldenstrom macroglobulinemia.

Empagliflozin has been found to lower the risk of death due to cardiovascular events and the number of first and recurrent heart failure hospitalizations.

Study results show that the frequency of adverse events decreased after the patients transitioned from combination therapy to monotherapy.

Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma.

All of the findings indicate that inadequate margin widths result in higher risks of distant recurrence and breast cancer mortality, as well as increased total recurrence.

Ivosidenib plus azacitidine shows benefits in event-free survival, overall survival, and clinical responses compared with placebo in patients with IDH1-mutated acute myeloid leukemia.

The functional and physical well-being and other scores from the survey are more favorable for those who were treated with the therapy, investigators say.

A researcher discusses how developing tertiary lymphoid structures may reach a greater maturity level within the tumor microenvironment.

Given that dendritic cells are necessary for anti-tumor response, researchers investigated which pathways stop these cells from performing their full functions.

The incremental use of drug combinations could prevent hospitalizations from heart failure among those who have higher ejection farction, a subgroup that struggles with insufficient data on treatments.

Despite significant advances in cancer treatment, molecular sequencing and enrollment of Black patients in clinical trials are still less than that of White and Asian patients.

Research suggests that HIV risk-reduction interventions could help adolescent males who are attracted to the same sex—and part of a minority ethnic and racial group—decrease HIV-risk sexual behaviors in the short-term.

Iheezo is a sterile, single use ophthalmic gel preparation.

Yvonne Chen, PhD, discusses her research to engineer more safe and effective next-generation CAR-T therapy for cancer immunotherapy.

IDH inhibitors show encouraging results in patients with myelodysplastic syndrome, but longer follow ups are needed in a larger patient population to confirm the results.

Expert discusses whether epigenetic programs regulate human T cell exhaustion and whether epigenetic-based strategies can be used to enhance T cell-based therapies.

Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Two Houston Methodist cancer researchers were granted a quarter of a million dollars each to study some of the most lethal cancers.

New research suggests patients with type 2 diabetes who have elevated glycated hemoglobin levels, even when on metformin, could benefit by adding glucose-lowering glargine.

New research has shown significant promise for the use of CAR T-cell therapies in solid tumors.

KIN-2787 is a potential treatment for BRAF class II or III alteration-positive and/or NRAS mutation-positive, metastatic or unresectable, stage IIB to IV malignant melanoma.

Continuous glucose monitors eliminate the need for frequent fingerstick use and carrying blood glucose monitoring supplies.

The forthcoming strategic plan will be focused on guiding future NIH research efforts to improve the health of all women throughout the life course.

For patients suffering from a higher left ventricular ejection fraction, a sodium-glucose cotransporter 2 inhibitor could decrease risk of hospitalization or death from heart failure.

Pharmacists play an important role in the recovery journey for patients who decide medication assisted treatment is right for them.

Combination treatment with ibrutinib found to increase median progression-free survival by 2.3 years compared to the placebo.